Safety and immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I first-in-human trial par de Graaf, H, Payne, RO, Taylor, I, Miura, K, Long, CA, Elias, SC, Zaric, M, Minassian, AM, Silk, SE, Li, L, Poulton, ID, Baker, M, Draper, SJ, Gbesemete, D, Brendish, NJ, Martins, F, Marini, A, Mekhaiel, D, Edwards, NJ, Roberts, R, Vekemans, J, Moyle, S, Faust, SN, Berrie, E, Lawrie, AM, Hill, F, Hill, AVS, Biswas, S

Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. par Payne, RO, Silk, SE, Elias, SC, Miura, K, Diouf, A, Galaway, F, de Graaf, H, Brendish, NJ, Poulton, ID, Griffiths, OJ, Edwards, NJ, Jin, J, Labbé, GM, Alanine, DGW, Siani, L, Di Marco, S, Roberts, R, Green, N, Berrie, EE, Ishizuka, AS, Nielsen, CN, Bardelli, M, Partey, FD, Ofori, MF, Barfod, L, Wambua, J, Murungi, LM, Osier, FH, Biswas, S, McCarthy, JS, Minassian, AM, Ashfield, R, Viebig, NK, Nugent, FL, Douglas, AD, Vekemans, J, Wright, GJ, Faust, SN, Hill, AV, Long, CA, Lawrie, AM, Draper, SJ

Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination par Minassian, AM, Silk, SE, Barrett, JR, Nielsen, CM, Miura, K, Diouf, A, Loos, C, Fallon, JK, Michell, AR, White, MT, Edwards, NJ, Poulton, ID, Mitton, CH, Payne, RO, Marks, M, Maxwell-Scott, H, Querol-Rubiera, A, Bisnauthsing, K, Batra, R, Ogrina, T, Brendish, NJ, Themistocleous, Y, Rawlinson, TA, Ellis, KJ, Quinkert, D, Baker, M, Lopez Ramon, R, Ramos Lopez, F, Barfod, L, Folegatti, PM, Silman, D, Datoo, M, Taylor, IJ, Jin, J, Pulido, D, Douglas, AD, de Jongh, WA, Smith, R, Berrie, E, Noe, AR, Diggs, CL, Soisson, LA, Ashfield, R, Faust, SN, Goodman, AL, Lawrie, AM, Nugent, FL, Alter, G, Long, CA, Draper, SJ